<p>Dr. Peterson is an MIT- and Harvard-trained faculty member at Washington University in St. Louis (a.k.a. WashU or WUSTL) School of Medicine (WUSM). WUSM is a perennially top-five US institution in terms of research funding and publishing and is tied to 19 Nobel Prize winners since its founding in 1909. Over his 15-year research career, Dr. Peterson has published in Nature, Science, and Cell and their affiliated journals and has received grant funding from the NIH, American Diabetes Association, the Nathan Shock Aging Center, Amazon Web Services amongst others. Dr. Peterson’s focus on longevity started with his PhD at MIT. At MIT, he made multiple seminal discoveries on rapamycin and the pathway it targets the mTOR pathway. Rapamycin and mTOR are arguably the most widely validated longevity therapy and pathway, respectively. At Harvard, Dr. Peterson trained under Erin O’Shea, PhD who now leads HHMI. There Dr. Peterson focused on longevity drug mechanisms, e.g., on the osteoporosis drug bisphosphonates and the diabetes drug metformin, which he has since carried with him into his academic lab and companies. In addition to his role at WashU and BIOIO, Dr. Peterson is a co-founder of Healthspan Technologies, which is developing mRNA lipid nanoparticle (LNP)-based therapeutics with a focus on vaccines for aging-accelerating infectious agents. Prior to his professional career, Dr. Peterson trained with the US Rowing Team from 1999-to 2001.</p>


Tim Peterson, PhD